In contrast to all other groups tested, LmAIO as monotherapy or in combination with α-PD-1 was able to decrease ALT and AST levels in plasma of tumor-bearing and tumor-free mice during the entire survival kinetic study (Fig. 8G, H). The gene discussed is GPT; the disease is neoplasm.